Providence Collaborates with Ontario Institute for Cancer Research to Explore mRNA Therapeutics
Friday, May 24, 2024
Providence Therapeutic Holdings Inc. (Providence), a company specializing in messenger RNA (mRNA) and lipid nanoparticle platform technology for vaccine and therapeutic development, has joined forces with the Ontario Institute for Cancer Research (OICR), a leading cancer research institute in Ontario. Together, they've forged a collaboration agreement aimed at advancing mRNA drug discovery and development.
This groundbreaking collaboration combines OICR's extensive expertise in cancer genomics and translational drug discovery with Providence's cutting-edge mRNA and lipid nanoparticle technology. The goal is to accelerate preclinical drug development and initiate new clinical initiatives addressing critical questions in clinical oncology.
Providence Therapeutics, expressed excitement about the collaboration, emphasizing the shared vision of advancing cancer research and treatment both locally and globally. Dr. Laszlo Radvanyi, President and Scientific Director of OICR, highlighted the potential of this partnership to revolutionize cancer prevention and treatment by leveraging Providence's mRNA technology alongside OICR's strengths in bioinformatics, genomics, and immunology.
The partnership between OICR and Providence will not only drive modern drug development in Canada but also launch new clinical initiatives benefiting individuals across the country. With domestic product development and manufacturing, Canadians will have priority access to participate in clinical oncology programs and receive new treatments.
Moreover, all programs resulting from this collaboration will grant Canada country-of-origin rights, ensuring affordable access to any medicines developed through these initiatives. This strategic partnership signifies a significant step forward in advancing cancer research and treatment, with profound potential impact on patients' lives and Canada's leadership in this field.
Source: prnewswire.com
